Ivacaftor/lumacaftor changes the lung microbiome and metabolome in cystic fibrosis patients
A. Neerincx (Amsterdam, Netherlands), K. Whiteson (Irvine, California, United States of America), J. Phan (Irvine, California, United States of America), P. Brinkman (Amsterdam, Netherlands), M. Abdel-Aziz (Amsterdam, Netherlands), E. Weersink (Amsterdam, Netherlands), J. Altenburg (Amsterdam, Netherlands), C. Majoor (Amsterdam, Netherlands), A. Maitland-Van Der Zee (Amsterdam, Netherlands), L. Bos (Amsterdam, Netherlands)
Source: Virtual Congress 2020 – Advances in cystic fibrosis: from microbiome to MRI
Session: Advances in cystic fibrosis: from microbiome to MRI
Session type: Oral Presentation
Number: 4337
Disease area: Paediatric lung diseases, Respiratory infections
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Neerincx (Amsterdam, Netherlands), K. Whiteson (Irvine, California, United States of America), J. Phan (Irvine, California, United States of America), P. Brinkman (Amsterdam, Netherlands), M. Abdel-Aziz (Amsterdam, Netherlands), E. Weersink (Amsterdam, Netherlands), J. Altenburg (Amsterdam, Netherlands), C. Majoor (Amsterdam, Netherlands), A. Maitland-Van Der Zee (Amsterdam, Netherlands), L. Bos (Amsterdam, Netherlands). Ivacaftor/lumacaftor changes the lung microbiome and metabolome in cystic fibrosis patients. 4337
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Pyrosequencing reveals transient cystic fibrosis lung microbiome changes with intravenous antibiotics Source: Eur Respir J 2014; 44: 922-930 Year: 2014
The microbiome in interstitial lung disease Source: Lung Science Conference 2015 Year: 2015
Bacterial infection and lung function in patients with cystic fibrosis Source: Eur Respir J 2005; 26: Suppl. 49, 615s Year: 2005
The cystic fibrosis lower airways microbial metagenome Source: ERJ Open Res 2016: 00096-2015 Year: 2016
The lung microbiome in chronic suppurative lung disease: cystic fibrosis and non-cystic fibrosis bronchiectasis Source: Eur Respir Monogr 2019; 83: 158-172 Year: 2019
Longitudinal changes in lung function and the association with pulmonary structure and infection in infants with cystic fibrosis Source: Annual Congress 2008 - Cystic fibrosis: novel aspects of airway function and inflammation Year: 2008
Molecular detection of complex microbial communities in sputa of patients with cystic fibrosis and non cystic fibrosis bronchiectasis Source: Annual Congress 2010 - Cystic fibrosis: lung disease infection and more Year: 2010
Season dynamics of inflammatory markers in patients with cystic fibrosis lung disease Source: Eur Respir J 2002; 20: Suppl. 38, 528s Year: 2002
The pulmonary microbiome in non-cystic fibrosis bronchiectasis. Source: International Congress 2017 – Bronchiectasis and NTM infections: epidemiology, phenotyping and therapeutic strategies Year: 2017
Comparative proteome analysis of lung tissue from patients with idiopathic pulmonary fibrosis, non-specific interstitial pneumonia and human donor lungs Source: Annual Congress 2008 - Management of idiopathic pulmonary fibrosis: what can we learn from the pathophysiology? Year: 2008
A molecular comparison of microbial communities in bronchiectasis and cystic fibrosis Source: Eur Respir J 2013; 41: 991-993 Year: 2013
Influence of the lung microbiome on antibiotic susceptibility of cystic fibrosis pathogens Source: Eur Respir Rev, 28 (152) 190041; 10.1183/16000617.0041-2019 Year: 2019
Metabolomic biomarkers predictive of early structural lung disease in cystic fibrosis Source: Eur Respir J 2016; 48: 1612-1621 Year: 2016
Comparison of progression in lung structure and lung function in children and adolescents with cystic fibrosis Source: Eur Respir J 2006; 28: Suppl. 50, 714s Year: 2006
Improving airway clearance in cystic fibrosis lung disease Source: Eur Respir Monogr 2014; 64: 169-187 Year: 2014
Genotype and progressive lung damage in adult cystic fibrosis patients Source: Eur Respir J 2003; 22: Suppl. 45, 502s Year: 2003
The pulmonary microbiome in sarcoidosis is similar to other parenchymal lung diseases Source: International Congress 2018 – Sarcoidosis: from basic research to patient outcomes Year: 2018
Microcirculation alterations in adult patients with cystic fibrosis Source: Eur Respir J 2006; 28: Suppl. 50, 262s Year: 2006
Stratifying infants with cystic fibrosis for disease severity using intestinal organoid swelling as a biomarker of CFTR function Source: Eur Respir J, 52 (3) 1702529; 10.1183/13993003.02529-2017 Year: 2018
Relations between the sinonasal development and the lung disease in cystic fibrosis patients Source: Eur Respir J 2005; 26: Suppl. 49, 103s Year: 2005